S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Stock market today: Asian stocks rise after Wall St retreats on concern economy weakening
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Stock market today: Asian stocks rise after Wall St retreats on concern economy weakening
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Stock market today: Asian stocks rise after Wall St retreats on concern economy weakening
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Stock market today: Asian stocks rise after Wall St retreats on concern economy weakening
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
LON:INDV

Indivior (INDV) Share Forecast, Price & News

GBX 1,590
+115.00 (+7.80%)
(As of 06/5/2023 ET)
Compare
Today's Range
1,566.20
▼
1,664.77
50-Day Range
1,369.60
▼
1,590
52-Week Range
1,330
▼
2,020
Volume
573,348 shs
Average Volume
417,479 shs
Market Capitalization
£2.19 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
GBX 2,350
ProfileAnalyst RatingsChartCompetitorsInsider TradesHeadlines

Indivior MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
47.2% Upside
GBX 2,340 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.78mentions of Indivior in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
£2.10 M Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.13 out of 5 stars

See Top Rated MarketRank™ Stocks Here

INDV stock logo

About Indivior (LON:INDV) Stock

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC has research collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Receive INDV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Indivior and its competitors with MarketBeat's FREE daily newsletter.

INDV Stock News Headlines

June 5, 2023 | reuters.com
Indivior opioid settlement makes purer M&A case
June 3, 2023 | msn.com
US drugmaker Indivior to pay $102.5 million to settle Suboxone monopoly claims
June 6, 2023 | Behind the Markets (Ad)
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
June 2, 2023 | finanznachrichten.de
Indivior PLC: Indivior Reaches Agreement with States' Attorneys General and District of Columbia to Resolve Antitrust Multi-District Litigation Claims
May 25, 2023 | uk.finance.yahoo.com
INDV.L - Indivior PLC
May 25, 2023 | finance.yahoo.com
Indivior To Participate In Upcoming Investor Conferences
May 23, 2023 | finance.yahoo.com
Indivior PLC Form 20-F Registration Statement for Additional US Listing Now Available; Trading on NASDAQ Expected to Commence on June 12th
May 22, 2023 | markets.businessinsider.com
FDA Approves Opiant's Nasal Spray 'Opvee' To Reverse Opioid Overdose
June 6, 2023 | Behind the Markets (Ad)
U.S. Loses to China in Shocking WAR GAMES
=== BREAKING === U.S. Loses to China in Shocking WAR GAMES Pentagon says new "living missile" key to winning a future conflict. Investors stand to reap 35,960% on shares of the small defense contractor that makes powerful new weapon. Get the name of the stock here >>>
May 22, 2023 | reuters.com
US FDA approves Opiant's spray for reversing opioid-related overdoses
May 22, 2023 | finance.yahoo.com
Indivior Announces U.S. Food and Drug Administration Approval of OPVEE® (nalmefene) Nasal Spray, An Opioid Overdose Rescue Medicine for Natural and Synthetic Opioids Like Fentanyl
April 27, 2023 | finance.yahoo.com
Indivior Announces Q1 2023 Financial Results
April 25, 2023 | finance.yahoo.com
Indivior To Participate In Bank of America Global Healthcare Conference 2023
March 2, 2023 | finance.yahoo.com
Indivior Completes Acquisition of Opiant Pharmaceuticals, Inc.
February 16, 2023 | finance.yahoo.com
FY 2022 Financial Results Announced
February 6, 2023 | finance.yahoo.com
Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLC
January 2, 2023 | finance.yahoo.com
Investing in Indivior (LON:INDV) three years ago would have delivered you a 861% gain
December 9, 2022 | finance.yahoo.com
Should You Be Excited About Indivior PLC's (LON:INDV) 73% Return On Equity?
December 7, 2022 | finance.yahoo.com
Indivior Capital Markets Day Highlights Strategy for Shareholder Value Creation and Attractive Medium-Term Profitable Growth Outlook
November 14, 2022 | finance.yahoo.com
Indivior To Acquire Opiant Pharmaceuticals
November 8, 2022 | finance.yahoo.com
Indivior Third Quarter 2022 Earnings: EPS: US$0.29 (vs US$0.18 in 3Q 2021)
October 27, 2022 | finance.yahoo.com
Indivior Announces Q3 2022 Financial Results
October 11, 2022 | finance.yahoo.com
Indivior PLC (LON:INDV) is favoured by institutional owners who hold 86% of the company
September 30, 2022 | finance.yahoo.com
Indivior Shareholders Approve Resolutions to Proceed with Additional U.S. Listing
September 27, 2022 | businesswire.com
Aelis Farma: Availability of the 2022 Half-year Financial Report - Business Wire
September 26, 2022 | law360.com
Two Funds Seek Invidior Antitrust Docs In Securities Case - Law360
September 7, 2022 | finance.yahoo.com
Indivior To Participate in Upcoming Investor Healthcare Events
See More Headlines

INDV Price History

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Drugs - Generic
Sub-Industry
N/A
Sector
Medical
Current Symbol
LON:INDV
CUSIP
N/A
CIK
N/A
Web
indivior.com
Phone
+44-1753-217800
Fax
N/A
Employees
885
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
GBX 2,340
High Stock Price Forecast
GBX 2,350
Low Stock Price Forecast
GBX 2,330
Forecasted Upside/Downside
+47.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
GBX (0.28)
Trailing P/E Ratio
N/A
Forward P/E Ratio
1,500.00
P/E Growth
-5.57
Net Income
£-50,000,000.00
Net Margins
-5.28%
Pretax Margin
N/A
Return on Equity
-32.90%
Return on Assets
8.23%

Debt

Debt-to-Equity Ratio
387.50
Current Ratio
1.08
Quick Ratio
1.52

Sales & Book Value

Annual Sales
£947 million
Price / Sales
2.31
Cash Flow
GBX 593.26 per share
Price / Cash Flow
2.68
Book Value
GBX 52 per share
Price / Book
30.58

Miscellaneous

Outstanding Shares
137,880,000
Free Float
N/A
Market Cap
£2.19 billion
Optionable
Not Optionable
Beta
-0.06

Key Executives

  • Mr. Mark Crossley
    CEO & Exec. Director
  • Mr. Ryan Preblick
    CFO & Exec. Director
  • Dr. Christian Heidbreder
    Chief Scientific Officer
  • Mr. Jason Thompson
    VP of Investor Relations
  • Ms. Cynthia Cetani
    Chief Integrity & Compliance Officer
  • Mr. Jeffrey W. Burris (Age 51)
    Chief Legal Officer
  • Mr. Jon Fogle
    Chief HR Officer
  • Mr. Richard Simkin
    Chief Commercial & Strategy Officer
  • Mr. Hillel West
    Chief Manufacturing & Supply Officer
  • Ms. Nina DeLorenzo
    Chief Global Impact Officer

Key Competitors

View All Competitors

Insiders

View All Insider Transactions













INDV Stock - Frequently Asked Questions

Should I buy or sell Indivior stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Indivior in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" INDV shares.
View INDV analyst ratings or view top-rated stocks.

What is Indivior's stock price forecast for 2023?

2 Wall Street research analysts have issued twelve-month target prices for Indivior's stock. Their INDV share price forecasts range from GBX 2,330 to GBX 2,350. On average, they expect the company's share price to reach GBX 2,340 in the next twelve months. This suggests a possible upside of 47.2% from the stock's current price.
View analysts price targets for INDV or view top-rated stocks among Wall Street analysts.

How have INDV shares performed in 2023?

Indivior's stock was trading at GBX 1,852 at the start of the year. Since then, INDV stock has decreased by 14.1% and is now trading at GBX 1,590.
View the best growth stocks for 2023 here.

What other stocks do shareholders of Indivior own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Indivior investors own include Bigblu Broadband (BBB), Futura Medical (FUM), Directa Plus (DCTA), Lakehouse (LAKE), Aquila Services Group (AQSG), Benchmark (BMK), Bodycote (BOY), CityFibre Infrastructure (CITY), Deltex Medical Group (DEMG) and Kingfisher (KGF).

What is Indivior's stock symbol?

Indivior trades on the London Stock Exchange (LON) under the ticker symbol "INDV."

How do I buy shares of Indivior?

Shares of INDV stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Indivior's stock price today?

One share of INDV stock can currently be purchased for approximately GBX 1,590.

How much money does Indivior make?

Indivior (LON:INDV) has a market capitalization of £2.19 billion and generates £947 million in revenue each year. The specialty pharmaceutical company earns £-50,000,000.00 in net income (profit) each year or GBX (0.28) on an earnings per share basis.

How many employees does Indivior have?

The company employs 885 workers across the globe.

How can I contact Indivior?

Indivior's mailing address is 103-105 Bath Road, SLOUGH, SL1 3UH, United Kingdom. The official website for the company is indivior.com. The specialty pharmaceutical company can be reached via phone at +44-1753-217800.

This page (LON:INDV) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -